Introduction 5-HT 3 receptors are ligand-gated ion channels that are responsible for fast synaptic neurotransmission in the central (CNS) and peripheral nervous systems (PNS). They are involved in physiological functions as diverse as the vomiting reflex, pain processing, reward, cognition, and anxiety, and modulate the release of neurotransmitters such as acetylcholine, cholecystokinin, dopamine, GABA, glutamate, and serotonin itself.
[1] To date, five different subunits (5-HT3A-5-HT3E) have been identified, but the homomeric 5-HT 3 A-and heteromeric 5-HT 3 ABcontaining receptors are the most fully characterized.
[1, 2] 5-HT 3 A receptors are located primarily in the CNS, while 5-HT 3 AB receptors may be more abundant in the PNS. [1, 3] 5-HT 3 receptors are members of the Cys-loop family of neurotransmitter-gated receptors that all share a pentameric structure of subunits surrounding a central ion-conducting pore. Each subunit has an extracellular domain, four transmembrane a helices (one of which contributes to the ion conducting pore) and an intracellular domain. [4] The agonist/competitive antagonist (orthosteric) binding site is located at the interface of two adjacent subunits and is formed by the convergence of three loops (loops A-C) from the principal (or +) subunit and three b sheets (loops D-E) from the adjacent complementary (or À) subunit.
The two 5-HT 3 receptor subtypes (5-HT 3 A and 5-HT 3 AB) can be distinguished by differences in their 5-HT concentration-response curves (increased EC 50 values and shallower Hill slopes), increased single channel conductance (5-HT 3 A = sub-pS; 5-HT 3 AB = 16-30 pS), increased rate of desensitization, decreased relative Ca 2 + permeability, and different current-voltage relationships (5-HT 3 A is inwardly rectifying, 5-HT 3 AB is linear). [1b, 5] Pharmacologically distinguishing 5-HT 3 A from 5-HT 3 AB receptors has historically required the use of compounds that bind in the pore, such as bilobalide, ginkgolide, and picrotoxinin. [6] In contrast, competitive ligands usually have very similar affinities at 5-HT 3 A and 5-HT 3 AB receptors. Recently, however, a quinoxaline compound (VUF10166) was identified that showed differences in both its binding affinity and functional properties at 5-HT 3 A and 5-HT 3 AB receptors (Figure 1 ). [7] Detailed studies of VUF10166 showed that these differences may stem from a second, allosteric, site only found in the 5-HT 3 AB receptor, the occupation of which may increase the rate of ligand dissociation from the adjacent orthosteric site.
The actions of a range of quinoxalines have also been previously studied at both 5-HT 3 A and native receptors and reUntil recently, discriminating between homomeric 5-HT 3 A and heteromeric 5-HT 3 AB receptors was only possible with ligands that bind in the receptor pore. This study describes the first series of ligands that can discriminate between these receptor types at the level of the orthosteric binding site. During a recent fragment screen, 2-chloro-3-(4-methylpiperazin-1-yl)-quinoxaline (VUF10166) was identified as a ligand that displays an 83-fold difference in [ 3 H]granisetron binding affinity between 5-HT 3 A and 5-HT 3 AB receptors. Fragment hit exploration, initiated from VUF10166 and 3-(4-methylpiperazin-1-yl)-quinoxalin-2-ol, resulted in a series of compounds with higher affinity at either 5-HT 3 A or 5-HT 3 AB receptors. These ligands reveal that a single atom is sufficient to change the selectivity profile of a compound. At the extremes of the new compounds were 2-amino-3-(4-methylpiperazin-1-yl)quinoxaline, which showed 11-fold selectivity for the 5-HT 3 A receptor, and 2-(4-methylpiperazin-1-yl)quinoxaline, which showed an 8.3-fold selectivity for the 5-HT 3 AB receptor. These compounds represent novel molecular tools for studying 5-HT 3 receptor subtypes and could help elucidate their physiological roles. vealed that these compounds can be relatively potent (sub-micromolar affinities) as antagonists, agonists, and partial agonists, with potential as novel therapeutics.
[8] There is particular interest, for example, in developing quinoxalines which are impermeable to the blood-brain barrier that would target peripheral 5-HT 3 receptors. [8a] None of these studies, however, have evaluated ligand affinities at specific 5-HT 3 receptor subtypes. In this manuscript, we report the synthesis and binding affinities of a series of quinoxalines and demonstrate subtle differences in structure-activity relationships (SAR) for the 5-HT 3 A and 5-HT 3 AB receptor subtypes using competition binding on recombinantly expressed receptors in HEK293 cells.
Results and Discussion

Chemistry
The pharmacophore features of lead compound 1 and VUF10166, and the effects of these features on 5-HT 3 A and 5-HT 3 AB receptor affinities, was explored by screening a series of compounds that contain the quinoxaline scaffold (Figure 1 b) . Intermediates 4-5 were synthesized via a two-step ring formation between 2-amino aniline 2 or 3 and the appropriate 2-oxo carboxylic acids (Scheme 1). After conversion into the corresponding 2-chloroquinoxalines with phosphorylchloride, subsequent nucleophilic aromatic substitution with N-methylpiperazine under microwave conditions gave compounds 6 and 7 in moderate to good yields.
Starting from commercially available chloro-quinoxalines 8 and 9, different synthetic routes were followed to synthesize compounds 10 and 11 (Scheme 2). Compound 10 was synthesized through two subsequent nucleophilic aromatic substitution reactions. First, the amine moiety was introduced by reacting compound 8 with ammonia in ethanol. Subsequently, the N-methylpiperazine group was introduced. Both reactions were performed under microwave conditions. Compound 11 was created in a similar manner, although conventional heating was used for this synthesis.
Commercially available quinoxaline-2,3(1H,4H)-dione (12) was treated with phosphorous pentabromide to form 2,3-dibromoquinoxaline (13), which was then allowed to react with N-methylpiperazine in toluene at reflux to yield compound 14 (Scheme 3). For compounds 16, 18, 19 , and 21, 2,3-dichloroquinoxaline (8) or 2-chloroquinoxaline (15) were reacted with the corresponding amines using various solvents and temperatures to yield 16, 17, 19 , and 20 in good yields. Boc-protected intermediates 17 and 20 were subsequently deprotected with a 4 m solution of hydrochloric acid in dioxane to give compounds 18 and 21 (Scheme 4). The regioselective synthesis of compound 22 was described earlier by our group. [9] Here, we used this compound as a precursor in the synthesis of compound 23 (Scheme 5). seems that the tautomeric form in which the aromatic nitrogen atom represents a hydrogen bond donor is not involved in binding, as the conversion of the R 2 alcohol functionality of 1 into a methoxy (compound 28) or ethoxy (compound 29) group results in compounds with comparable affinities. However, larger ether analogues are not favorable for binding, as observed for compounds 30-32 in which the cyclohexyl, phenyl, and benzyl ether derivatives have~100-fold lower affinities. When the hydroxy group of 1 at R 2 was changed to a different polar moiety (e.g., an amine moiety, as in compound 10), the high affinity was maintained. A decreased affinity was observed for compound 26, which incorporates a methyl group (which is electron-donating) at the R 2 position, relative to VUF10166. Addition of an electron-withdrawing CF 3 group (compound 27) results in an even larger decrease in 5-HT 3 A receptor affinity. Compounds that have chlorine or bromine atoms at this position have sub-nanomolar affinities (VUF10166 and 14), indicating that the SAR in this position is very subtle, and an interplay between inductive and resonance effects cannot be ruled out.
For R 2 = Cl (VUF10166), different basic moieties were introduced. A small drop in affinity results from replacing R 1 = Nmethylpiperazine (VUF10166) with R 1 = N-methylhomopiperazine (16), but a~1000-fold drop in affinity is observed for R 1 = N-methylpyrrolidin-3-amine (18) . As the methylpiperazine moiety leads to the most potent compounds at 5-HT 3 A receptors, this basic group was used in the R 1 position when exploring the effects of different chlorine substitution patterns at the R 3 position. Addition of a 6-Cl at R 2 (compound 23) causes a~10-fold drop in affinity, and a second chlorine atom at position R 3 (6,7-Cl, 11) results in another~10-fold decrease. Again, VUF10166 (R 3 = H) shows the highest affinity for the 5-HT 3 A receptor. For compounds with R 2 = OH (1), a similar trend is observed. Affinity at the 5-HT 3 A receptor is highest for R 3 = H (1) and decreases significantly for both compound 22 (R 3 = 6-Cl) and 34 (R 3 = 6,7-Cl), which both have a pK i in the mid-nanomolar range.
The same modifications to R 1 and R 3 were made for the most simple 2-N-methylpiperazine quinoxaline compound of the series (R 2 = H, 24), which has a pK i of 8.21. Addition of chlorine atoms at position R 3 (33, 7) results in compounds with similar affinity at the 5-HT 3 A receptor. Finally, replacement of the N-methylpiperazine group of compound 24 with an N-methylhomopiperazine group (19) has no effect on 5-HT 3 A receptor affinity, but for R 1 = N-methylpyrrolidin-3-amine (21), a small decrease in affinity is observed. This is different to what is observed for R 2 = Cl, where basic moieties other than the N-methylpiperazine group resulted in more pronounced differences in affinity (e.g., compare 19 and 21 with 16 and 18, respectively).
Affinity differences at 5-HT 3 A and 5-HT 3 AB receptors
The affinity of compound 1 is slightly higher (2.7-fold) for 5-HT 3 AB receptors than for 5-HT 3 A receptors. Methoxy and ethoxy analogues 28 and 29 both show a 10-fold decrease in affinity at 5-HT 3 AB receptors relative to compound 1; in contrast, these modifications do not result in a change in affinity at the 5-HT 3 A receptor. The larger ether analogues 30-32 have pK i values of~7 for the 5-HT 3 AB receptor, which are similar to their affinities for the homomeric receptor. Replacement of the alcohol moiety with an amine moiety (compound 10) resulted in a large decrease in affinity (~70-fold) for 5-HT 3 AB receptors but had little effect on the affinity for 5-HT 3 A receptors. Similar affinities are observed at both the 5-HT 3 A and 5-HT 3 AB receptors for compounds that have methyl and ethyl substituents in the R 2 position (i.e., 26 and 6, respectively), as well as for trifluoromethyl derivative 27. For the halogen-substituted compounds, a different trend is observed. For R 2 = Br, the pK i for 5-HT 3 AB receptors is close to 9, which is similar to that for 5-HT 3 A receptors, but the affinity of VUF10166 (R 2 = Cl) is significantly decreased at 5-HT 3 AB receptors, resulting in a~100-fold difference relative to 5-HT 3 A receptors. The effect of replacing R 1 = N-methylpiperazine (VUF10166) for R 1 = N-methylhomopiperazine while R 2 = Cl (16) is negligible at 5-HT 3 AB receptors, which is again different to what is observed at 5-HT 3 A receptors. For R 1 = N-methylpyrrolidin-3-amine (18), a > 10-fold decrease in affinity for 5-HT 3 AB receptors is observed. 5-HT 3 AB receptor affinities for compounds with a chlorine atom at position R 2 (VUF10166, 23, and 11) do not change substantially when increasing numbers of chlorine atoms are added at the R 3 position, although compound 11 has the lowest 5-HT 3 AB receptor affinity of this subset. This is different to what is observed for the 5-HT 3 A receptor affinities of these compounds, where addition of chlorine at R 3 resulted in a large decrease in affinity. When R 2 = OH, compound 1 (R 3 = H) had the highest 5-HT 3 AB receptor affinity, compound 22 (R 3 = 6-Cl) showed a~10-fold decrease in affinity, and a further~10-fold decrease in affinity was observed for compound 34 (R 3 = 6,7-Cl). 5-HT 3 A receptor affinities shown by 22 and 34 are similar. When R 2 = H, the highest 5-HT 3 AB receptor affinity was observed for R 3 = H (24), but a~100-fold drop in affinity was observed for R 3 = 6-Cl (33) and only a~10-fold drop for R 3 = 6,7-Cl (7). The effect on 5-HT 3 AB receptor affinity when replacing R 1 = N-methylpiperazine (24) for R 1 = N-methylhomopiperazine (19), while R 2 = H, is a~45-fold decrease in affinity. For compound 21, a similar lowering in 5-HT 3 AB receptor affinity is observed. This is in contrast to what is observed for 5-HT 3 A receptors and can primarily be attributed to the sub-nanomolar affinity of compound 24 at 5-HT 3 AB receptors, which is almost 10-fold higher than its 5-HT 3 A receptor affinity. Table 1 shows that compound 24 shows the highest selectivity for 5-HT 3 AB over 5-HT 3 A receptors (~10-fold), and VUF 10166 has the highest selectivity for 5-HT 3 A over 5-HT 3 AB receptors (~100-fold). The difference between these two compounds is solely the atom at position R 2 , R 2 = H for compound 24 and R 2 = Cl for VUF10166. When the hydrogen atom is replaced with a chlorine atom, the 5-HT 3 A receptor affinity increases~40-fold, while the affinity for 5-HT 3 AB receptors decreases~20-fold. Both of these compounds comprise the N-methylpiperazine moiety, which is the preferred basic group for selectivity. For 5-HT 3 A receptor affinity, R 2 = Cl (VUF10166) is superior, with Br (14), Et (6), OMe (28), and OEt (29) having similar lower affinities. For the 5-HT 3 AB receptor, an alcohol moiety at position R 2 (as observed for compound 1) is preferred, but a hydrogen atom at R 2 also results in high affinity (compound 24). At 5-HT 3 AB receptors, R 2 = Br and the smaller alkyl (26, 6) and ether analogues (28 and 29) also have high affinities, whereas incorporation of larger ether groups at R 2 results in decreased affinity. However, for R 2 = Cl (VUF10166) and NH 2 (10), only 5-HT 3 AB receptor affinity is decreased, resulting in 100-and 10-fold selectivity for 5-HT 3 A over 5-HT 3 AB receptors, respectively. Different substitution patterns at the R 3 position also caused marked changes. For example, when R 2 = Cl, replacement of R 3 = H (VUF10166) with a chlorine atom results in a~10-fold (R 3 = 6-Cl, 23) or~100-fold (R 3 = 6,7-Cl, 11) decrease in affinity for the 5-HT 3 A receptor, but this replacement does not have a large effect on 5-HT 3 AB receptor affinity. When R 2 = H, the affinity for 5-HT 3 A receptors does not show a large difference upon addition of chlorine atoms to the R 3 position, but the 5-HT 3 AB receptor affinity changes significantly. It can be concluded that, in either case, the greatest 5-HT 3 receptor subtype selectivity is achieved for R 1 = N-methylpiperazine.
5-HT 3 receptor binding sites
Orthosteric binding sites in 5-HT 3 AB receptors could theoretically exist at A + AÀ, A+ BÀ, B+ AÀ, and B+ BÀ interfaces, but the majority of 5-HT 3 receptor-competitive ligands only bind to an A + AÀ interface. [4, 10] There is evidence, however, that at least one of the quinoxaline compounds studied here (VUF10166) binds to both an A + AÀ and an A + BÀ interface; binding to the A + BÀ interface may decrease the affinity of ligands binding to the A + AÀ site by allosterically increasing the rate of ligand dissociation. [7] Other quinoxalines may similarly bind to both sites; thus, to identify potential interactions, we constructed models of the two interfaces.
Homology models were based on a tropisetron-bound AChBP crystal structure (PDB code: 2WNC) as no quinoxalinebound Cys-loop receptor structure has been solved to date, and tropisetron is the closest structurally related compound to those described here (Figure 3) . Tropisetron is an antagonist at the 5-HT 3 receptor but can act as an agonist at some nACh receptors; [11] thus, it is an ideal choice from the available structures as quinoxalines can act as both agonists and antagonists at 5-HT 3 receptors, though they were not evaluated in this study. As with all homology models, caution must be applied in data interpretation, especially now that recent electron microscope images of the nACh receptor have shown that the difference between the structure of unbound and agonistbound binding site sites is less than that observed in AChBP. [12] Nevertheless, it is likely that our compounds adopt a broadly similar orientation to tropisetron; therefore, the models serve as means of identifying residues that could potentially be responsible for the differences in affinities of the quinoxaline ligands at 5-HT 3 A and 5-HT 3 AB receptors. As discussed below, several of the identified residues are known to interact with a range of 5-HT 3 receptor ligands (Figures 2 and 3) . [4] Some of these are the same in both A + AÀ and A + BÀ binding sites and are unlikely to be responsible for differences in affinity, while others are different and may provide possible explanations for the varied ligand affinities at the two receptor subtypes. [13] Our homology models predict that both A + AÀ and A + BÀ binding sites contain these residues, providing an aromatic environment to accommodate the positively charged moiety that is a well-known pharmacophore feature of 5-HT 3 ligands. [14] Another pharmacophore feature, a hydrogen bond acceptor (HBA), is observed in both models as an interaction between the carbonyl oxygen atom of tropisetron and wat 2 from a water network that has been observed in AChBP crystal structures; water molecules in this network are also stabilized by interactions with the backbone of the protein and the side chain of Tyr 234. In both binding sites, the positively charged moieties of tropisetron are also stabilized by ionic interactions with Glu 129 (loop A), and by a hydrogen bonding interaction between the protonated nitrogen atom and the carbonyl backbone of Trp 183. Mutagenesis studies have shown that both Glu 129 and Trp 183 are essential for 5-HT function and granisetron binding. [13] Because the principle faces of both A + AÀ and A + BÀ binding sites are identical, we must look toward the AÀ and BÀ interfaces for differences between the two binding sites. Of the differing residues, A Ile 71 /B Phe 71 , A Arg 92 /B Gln 92 and A Gln 151 /B Glu 151 are closest to tropisetron, and might also be expected to interact with the structurally related quinoxaline ligands described here. A Ile 71 /B Phe 71 lies in the b1-strand, close to binding loop A. However, A Ile 71 mutations to Ala and Leu had no effect on granisetron binding affinity, suggesting the residue at this location does not affect ligand binding.
[13] Conversely substitution of A Arg 92 changed the affinities of several 5-HT 3 ligands, including 5-HT and granisetron, and we have previously speculated that a cation-p interaction could exist between A Arg 92 and the aromatic parts of (iso)quinolines and quinazolines, as it does with granisetron. [10, 15] As this type of interaction would be absent in an A + BÀ site (as Gln is a neutral residue), quinoxalines might adopt quite a distinct orientation in this binding pocket. In support of this speculation, we have previously shown that introduction of a Cys substitution at this location has no effect on 5-HT or granisetron, but eliminates the allosteric effects of VUF10166 in heteromeric receptors. [7] Similarly, the change in charge at location 151 (A Gln 151 /B Glu 151 ) could have a significant effect on ligand binding properties. Although the effect of this residue has not yet been studied, mutation of the closely located B Tyr 153 residue also eliminates the allosteric effects of VUF10166, showing that this region influences binding at the B interface. [7] For VUF10166, the effects of these B-substitutions are known to alter both the binding properties and the functional response, but for the other quinoxalines studied here, it has yet to be determined whether the differing binding affinities also translate into functional changes.
Conclusions
In summary, most quinoxaline compounds examined here show no difference in their affinities at 5-HT 3 A and 5-HT 3 AB receptors, and we suggest that these compounds may only bind to the A + A binding site that is found in both receptor types, consistent with all other 5-HT 3 receptor-competitive ligands. [10, 16] Some, however, show significant differences and thus may bind to the A + BÀ interface as has previously been shown for VUF10166. [10] These novel ligands could be valuable in both experimental and computer-aided drug design, with potential for the development of novel therapeutic agents.
Experimental Section
Chemistry: Chemicals and solvents were purchased from SigmaAldrich and used as received. Unless indicated otherwise, all reactions were carried out under an inert atmosphere of dry N 2 . TLC analyses were performed with Merck F254 alumina silica plates using UV visualization or staining. Column purifications were carried out automatically using the Biotage equipment. All HRMS spectra were recorded on Bruker microTOF mass spectrometer using ESI in positive ion mode. . Systematic names for molecules according to IUPAC rules were generated using the ChemDraw AutoNom program. Purity was determined using a Shimadzu HPLC/MS workstation with a LC-20AD pump system, SPD-M20A diode array detection, and an LCMS-2010 EV mass spectrometer. An Xbridge C 18 5 mm column (100 mm 4.6 mm) was used. Compound purities were calculated as the percentage peak area of the analyzed compound by UV detection at 230 nm. Solvents used were as follows: solvent B = CH 3 CN 0.1 % formic acid; solvent A = H 2 O 0.1 %. The analysis was conducted using a flow rate of 1.0 mL min À1 , starting at 5 % B with a linear gradient to 90 % B in 4.5 min, then 1.5 min at 90 % B with a linear gradient to 5 % B in 0.5 min, and then 1.5 min at 5 % B, with a total run time of 8 min.
Compounds 24-34 were synthesized by our group as described by Smits et al. [9] 3-Ethyl-3,4-dihydroquinoxalin-2(1H)-one (4): Benzene-1,2-diamine (2) (1.07 g, 28.4 mmol) and 2-oxobutanoic acid (2.90 g, 28.4 mmol) were dissolved in 50 mL CH 3 OH, and the resulting solution was stirred overnight at room temperature. The resulting precipitate was collected via filtration over a Büchner funnel. The precipitate was washed with cold CH 3 OH and dried in a vacuum oven to yield 2.25 g (12. 2-Ethyl-3-(4-methylpiperazin-1-yl)quinoxaline (6): A solution of 4 (1.64 g, 9.39 mmol) in phosphoryl trichloride (100 mL) was stirred at 100 8C for 1 h. The reaction mixture was then concentrated under reduced pressure. H 2 O was added to the remaining solid, then the mixture was extracted with CH 2 Cl 2 . The organic layers were combined, dried over Na 2 SO 4 , and concentrated under reduced pressure to yield 1.59 g (8.24 mmol, 88 %) of 2-chloro-3-ethylquinoxaline as a dark-pink solid: 03 (m, 1 H), 8.02-7.95 (m, 1 H), 7 .79-7.67 (m, 2 H), 3.17 (q, J = 7.5 Hz, 2 H), 1.44 ppm (t, J = 7.5 Hz, 3 H). Next, 2-chloro-3-ethylquinoxaline (555 mg, 2.88 mmol) was dissolved in N-methylpiperazine (2 mL), and the resulting solution was heated at 120 8C for 15 min using microwave (mw) radiation. After cooling to room temperature, excess N-methylpiperazine was removed under reduced pressure, and the product was purified over SiO 2 (EtOAc/ Et 3 1 H) . Then, 2,6,7-trichloroquinoxaline (66 mg, 0.28 mmol) was dissolved in EtOAc (2 mL), N-methylpiperazine (0.1 mL, 0.90 mmol) was added, and the resulting solution was heated at 160 8C for 1 h using microwave radiation. After cooling to room temperature, EtOAc and excess N-methylpiperazine were removed under reduced pressure, and the product was purified over SiO 2 (EtOAc/Et 3 3-(4-Methylpiperazin-1-yl)quinoxalin-2-amine (10): 2,3-Dichloroquinoxaline (8) (1.99 g, 10.0 mmol) was dissolved in a 2 m NH 3 solution in EtOH (5.5 mL) and heated in the microwave at 100 8C for 2 h. The solvent was then removed under reduced pressure, and the residue was purified over SiO 2 (CH 2 Cl 2 /EtOAc, 100:0 to 60:40, v/v) to give 300 mg (1.67 mmol, 17 %) of 3-chloroquinoxalin-2-amine. Next, 3-chloroquinoxalin-2-amine (150 mg, 0.84 mmol) and N-methylpiperazine (1.0 mL, 9.02 mmol) were dissolved in THF (4 mL). The resulting mixture was heated under microwave conditions at 150 8C for 40 min, quenched with H 2 O, and extracted with EtOAc. The organic layers were combined, dried (Na 2 SO 4 ), and concentrated under reduced pressure. The product was crystallized from EtOAc to give 100 mg (0.41 mmol, 49 %) of 10 as a darkyellow solid: , 1 H), 7.50-7.33 (m, 2 H), 4.98 (s, 2 H) were suspended in toluene (200 mL) and heated at 160 8C for 3 h. After cooling to room temperature, ice water (200 mL) was added to the solution, and the mixture was stirred vigorously for 30 min. The mixture was extracted with toluene, washed with 1 n NaOH (100 mL), dried over MgSO 4 , filtered, and concentrated under vacuum. The crude product was purified over SiO 2 (CH 2 Cl 2 /n-heptanes, 1:2, v/v) to give 505 mg (12. 2-Bromo-3-(4-methylpiperazin-1-yl)quinoxaline (14) : 2,3-Dibromoquinoxaline (13) (505 mg, 1.75 mmol), N-methylpiperazine (176 mg, 1.75 mmol), and Et 3 N (177 mg, 1.75 mmol) were dissolved in toluene (50 mL). The solution was stirred at 160 8C for 6 h. After cooling to room temperature, H 2 O was added, and the emulsion was extracted with toluene. The combined organic extracts were dried over MgSO 4 2-Chloro-3-(4-methyl-1,4-diazepan-1-yl)quinoxaline (16): 2,3-Dichloroquinoxaline (8) (1.00 g, 5.0 mmol), N-methyl-1,4-diazepane (0.86 mL, 7.50 mmol), and Et 3 N (0.70 mL, 5.00 mmol) were dissolved in toluene (50 mL). The solution was stirred overnight at reflux. After cooling to room temperature, H 2 O was added, and the resulting mixture was extracted with toluene, dried over MgSO 4 
tert-Butyl
(1-(3-chloroquinoxalin-2-yl)pyrrolidin-3-yl)(methyl)-carbamate (17): 2,3-dichloroquinoxaline (0.54 g, 2.71 mmol) was dissolved in DMF (30 mL). K 2 CO 3 (0.37 g, 2.71 mmol) and tert-butyl methyl(pyrrolidin-3-yl)carbamate (0.49 g, 2.47 mmol) were added, and the mixture was stirred at 90 8C for 4 h. The mixture was cooled to room temperature, diluted with H 2 O, and extracted with Et 2 O. The combined organic layers were dried over MgSO 4 and concentrated under reduced pressure to give 0.68 g of 17, which was directly used in the synthesis of 18. tert-Butyl methyl(1-(quinoxalin-2-yl)pyrrolidin-3-yl)carbamate (20): 2-Chloroquinoxaline (1.79 g, 10.9 mmol) was dissolved in DMF (50 mL). K 2 CO 3 (1.51 g, 10.9 mmol) and tert-butyl methyl(pyrrolidin-3-yl)carbamate (2.00 g, 10.0 mmol) were added, and the mixture was stirred at 90 8C for 6 h. The mixture was cooled to room temperature, diluted with H 2 O, and extracted with Et 2 O. The combined organic layers were dried over MgSO 4 and concentrated under reduced pressure to give 3.28 g of 20, which was directly used in the synthesis of 21.
N-Methyl-1-(quinoxalin-2-yl)pyrrolidin-3-amine (21): Compound 20 (2.95 g) was dissolved in dioxane (20 mL) and stirred at room temperature. A solution of 4 m HCl in dioxane (10 mL) was added dropwise, and precipitation was observed. The suspension was stirred overnight and filtered over a Büchner funnel. The residue was washed with 1,4-dioxane and dried under vacuum to yield 1.33 g of 21 as a beige solid (5.02 mmol, 56 %): 
